Last updated: November 13, 2026
WELIREG, Merck’s belzutifan, is the first approved inhibitor of hypoxia-inducible factor-2 alpha, or HIF-2α. Its commercial trajectory changed materially after FDA approval in advanced renal cell carcinoma in 2023. Reported U.S. and global sales increased from roughly $240 million in 2022 to about $410 million in 2023 and approximately $700 million in 2024, according to Merck’s annual reporting. The principal commercial risks are competition in advanced renal cell carcinoma, anemia and hypoxia management, clinical differentiation against established immunotherapy and VEGF-targeted regimens, and eventual generic entry after patent and regulatory protections expire.
What is WELIREG and how does it work?
WELIREG is an oral small-molecule medicine containing belzutifan. It inhibits HIF-2α, a transcription factor involved in tumor growth, angiogenesis, and adaptation to low-oxygen conditions.
The FDA approved WELIREG in August 2021 for adults with von Hippel-Lindau disease who require treatment for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors and do not require immediate surgery. The FDA expanded the label in December 2023 for adults with advanced renal cell carcinoma after treatment with a PD-1 or PD-L1 inhibitor and a VEGF-targeted therapy.[1,2]
| Item |
WELIREG detail |
| Active ingredient |
Belzutifan |
| Sponsor |
Merck & Co., Inc. |
| Original FDA approval |
August 13, 2021 |
| Initial indication |
VHL disease-associated RCC, CNS hemangioblastomas, and pancreatic neuroendocrine tumors |
| RCC expansion |
December 14, 2023 |
| Dosage form |
40 mg tablets |
| Recommended dose |
120 mg orally once daily |
| Mechanism |
HIF-2α inhibition |
| Therapeutic class |
Targeted oncology |
| Primary commercial markets |
Advanced RCC and VHL-associated tumors |
Belzutifan is differentiated from immune checkpoint inhibitors and VEGF receptor tyrosine-kinase inhibitors because it acts on the tumor’s hypoxia-response pathway. Its clinical use is constrained by anemia, hypoxia, and embryo-fetal toxicity. The FDA label requires hemoglobin monitoring and includes warnings for anemia and hypoxia.[3]
How has WELIREG revenue changed since launch?
WELIREG has moved from an orphan oncology product into a broader renal cell carcinoma franchise.
| Fiscal year |
Approximate Merck WELIREG sales |
Commercial driver |
| 2022 |
$240 million |
VHL demand and early adoption |
| 2023 |
$410 million |
RCC approval and post-approval launch |
| 2024 |
$700 million |
Expansion into previously treated advanced RCC |
| 2025 onward |
Depends on RCC penetration and pipeline expansion |
Market access, earlier-line use, and combination studies |
The 2023 RCC approval expanded the addressable population well beyond VHL disease. VHL is a rare inherited cancer syndrome, while advanced RCC is a substantially larger commercial market. The 2024 sales increase indicates that the RCC label, rather than VHL alone, is driving the asset’s financial trajectory.[4]
A reasonable base-case commercial model places peak annual sales in the low-single-digit billions if Merck secures additional RCC use and maintains premium oncology pricing. A lower case would result from limited uptake after prior immunotherapy and VEGF-targeted therapy, competitive pressure from combination regimens, and tolerability-related discontinuations.
What is the revenue exposure to renal cell carcinoma?
Advanced RCC is the main source of future revenue exposure. The VHL market provides a durable orphan base but is too small to support large-scale growth independently.
The RCC opportunity is concentrated in patients who have already received both a PD-1 or PD-L1 inhibitor and a VEGF-targeted agent. That sequencing limits the immediately eligible population compared with first-line RCC therapies. Merck’s growth opportunity depends on:
- Increased physician adoption after immunotherapy and VEGF-targeted treatment.
- Use in additional lines of therapy.
- Positive results from combination studies.
- Potential movement into earlier treatment settings.
- Expansion outside the United States.
What clinical data support WELIREG’s commercial position?
The RCC approval was based primarily on LITESPARK-005, a randomized phase 3 trial comparing belzutifan with everolimus in previously treated advanced RCC. The trial showed improved progression-free survival, but overall survival was not superior at the initial analysis.[2]
In VHL disease, the approval relied on tumor response and disease-control data across VHL-associated RCC, CNS hemangioblastomas, and pancreatic neuroendocrine tumors. The VHL setting is clinically distinctive because treatment can delay or reduce the need for repeated surgeries.
| Clinical setting |
Commercial implication |
| VHL-associated RCC |
Establishes orphan-market base and long-duration treatment opportunity |
| VHL CNS hemangioblastomas |
Expands utility beyond conventional RCC drugs |
| VHL pancreatic neuroendocrine tumors |
Increases value within genetically defined disease |
| Previously treated advanced RCC |
Provides the main large-market growth driver |
| Earlier-line or combination RCC |
Key upside opportunity, subject to clinical and regulatory success |
WELIREG’s clinical positioning is strongest where a systemic, oral, non-VEGF treatment is valuable. Its commercial positioning is weaker when physicians prioritize regimens with established overall-survival advantages or when anemia and hypoxia are difficult to manage.
What patents protect WELIREG?
WELIREG is protected by patents covering belzutifan and HIF-2α inhibitor chemistry. Representative U.S. patent families include patents directed to HIF-2α inhibitors, pharmaceutical compositions, and related therapeutic use.
| Representative U.S. patent |
General subject matter |
Approximate statutory term |
| U.S. Patent No. 10,221,221 |
HIF-2α inhibitor compounds and related claims |
Mid-2030s |
| U.S. Patent No. 10,570,158 |
HIF-2α inhibitor chemistry and pharmaceutical claims |
Mid-2030s |
| U.S. Patent No. 11,034,715 |
Related HIF-2α inhibitor claims |
Mid-to-late 2030s |
The exact enforceable term depends on patent-term adjustment, terminal disclaimers, patent-family structure, and any patent-term extension or pediatric exclusivity. The principal composition-of-matter and compound patent protection is generally expected to extend into the 2034-2036 period in the United States, with later expirations possible for secondary patents.
Merck obtained belzutifan through its 2019 acquisition of Peloton Therapeutics. The transaction included an upfront payment of approximately $1.05 billion and potential milestone payments of up to approximately $2.15 billion.[5] The deal gave Merck control of the clinical-stage HIF-2α program and the underlying patent estate.
What formulations are protected by WELIREG patents?
The commercial product is a film-coated oral tablet supplied in 40 mg strength. Patent protection may extend beyond the active compound to pharmaceutical compositions, solid forms, dosing regimens, and treatment methods.
Formulation patents can delay or complicate generic substitution when they cover:
- Tablet composition and excipients.
- Crystalline or polymorphic forms.
- Stability characteristics.
- Specific dose combinations.
- Manufacturing processes.
- Methods of treating VHL disease or advanced RCC.
The commercial importance of formulation patents depends on whether they are listed in the FDA Orange Book and whether a generic applicant can design around them. Composition patents usually provide the strongest barrier. Method-of-use and formulation patents are more vulnerable to carve-outs, invalidity challenges, or non-infringing product designs.
When does WELIREG lose exclusivity?
WELIREG faces multiple, overlapping exclusivity dates rather than a single loss-of-exclusivity event.
| Protection |
Expected timing |
Effect |
| VHL orphan-drug exclusivity |
August 2028 |
Blocks approval of the same drug for the same orphan indication, subject to statutory exceptions |
| RCC clinical-investigation exclusivity |
Approximately late 2026 |
Limits reliance on the qualifying clinical data for the approved RCC indication |
| Core patent protection |
Generally 2034-2036 or later depending on patent |
Main U.S. barrier to ANDA approval and commercial launch |
| Secondary patents |
Potentially through the late 2030s |
May affect formulations, methods, or specific uses |
| Generic launch |
Most likely after relevant patents are resolved or expire |
Depends on Paragraph IV litigation and settlement terms |
The 2026 and 2028 regulatory exclusivity dates do not necessarily permit generic launch. A generic applicant must still address listed patents, and the effective launch date may be controlled by patent litigation, settlement, court judgment, or a successful validity or non-infringement position.
What is the Orange Book status of WELIREG?
WELIREG is an FDA-approved small-molecule drug and is eligible for ANDA-based generic competition. It is not a biologic, so biosimilar pathways do not apply.
Orange Book-listed patents are the key legal reference for generic challenges. A complete assessment requires matching each listed patent to its expiration date, pediatric extension, patent-term adjustment, and approved indication. The relevant WELIREG estate includes compound, composition, and method-of-use protection, although the commercial strength of each patent depends on its precise Orange Book listing and claim scope.[6]
The main regulatory distinction is:
- Generic applicants can file an ANDA.
- They may certify that listed patents have expired or will expire before launch.
- They may file a Paragraph IV certification alleging that patents are invalid, unenforceable, or not infringed.
- A timely patent infringement action can trigger a 30-month stay of ANDA approval, subject to statutory exceptions and court decisions.
Which companies are challenging WELIREG patents?
No major public Paragraph IV litigation affecting WELIREG has been broadly reported in the cited materials through the available record. The absence of a disclosed challenge does not eliminate future risk. Generic companies typically assess high-value oncology products before patent expiry, and WELIREG’s projected sales make it a potential target for ANDA filings.
Likely generic entrants would include large U.S. and international manufacturers with oncology portfolios. The most important legal questions would concern:
- Validity of the core belzutifan compound claims.
- Written description and enablement for broad genus claims.
- Obviousness over earlier HIF-2α inhibitor disclosures.
- Infringement of composition and solid-form patents.
- Applicability of method-of-use patents to a carved-out label.
- Regulatory exclusivity for VHL and RCC indications.
How strong is the WELIREG patent estate?
The patent estate is commercially strong through the first half of the 2030s because it protects a differentiated active ingredient with orphan and large-market oncology indications. The strongest protection is expected to come from composition-of-matter claims covering belzutifan or closely defined HIF-2α inhibitor structures.
The estate is less secure against:
- Prior-art attacks on broad chemical claims.
- Design-around compounds or formulations.
- Skinny-label generic products that omit protected methods.
- Challenges to secondary patents.
- Court findings that a patent is invalid or not infringed.
- Settlement agreements allowing an earlier authorized generic or licensed launch.
Patent strength is therefore high for the near and medium term but cannot be measured solely by the latest expiration date. Claim breadth, Orange Book listing status, prosecution history, and litigation outcomes will determine effective exclusivity.
What competitive forces affect WELIREG?
WELIREG competes indirectly with multiple therapy classes rather than with a single branded product.
| Competitive category |
Examples |
Impact on WELIREG |
| PD-1/PD-L1 therapies |
Pembrolizumab and nivolumab-based regimens |
Establish standard first-line treatment |
| VEGF-targeted therapies |
Axitinib, cabozantinib, lenvatinib, pazopanib |
Compete for sequencing and later-line use |
| mTOR inhibition |
Everolimus |
Comparator in LITESPARK-005 |
| Combination regimens |
Immunotherapy plus VEGF or other targeted agents |
May reduce later-line patient volume |
| Investigational HIF-2α inhibitors |
Other oral HIF-2α programs |
Could erode mechanism-based differentiation |
| Generic belzutifan |
Future ANDA products |
Creates direct price competition after patent expiry |
The strongest current competitive threat is treatment sequencing. Physicians may choose cabozantinib, lenvatinib-based regimens, or other targeted therapies before belzutifan depending on guideline position, prior exposure, tolerability, and payer policy.
What FDA regulatory developments could increase WELIREG sales?
Additional approvals in earlier-line RCC, combination therapy, or other HIF-2α-sensitive tumors could materially expand sales. Merck’s LITESPARK clinical program has evaluated belzutifan in combination and comparative settings across RCC.
Potential regulatory catalysts include:
- First-line or intermediate-line RCC approval.
- Combination use with immune checkpoint inhibitors.
- Additional VHL-related indications.
- Treatment of other tumors with HIF-2α pathway dependence.
- International reimbursement approvals.
- Label changes that improve dosing flexibility or patient selection.
Regulatory risk remains significant. A failure to demonstrate overall-survival benefit, an unfavorable safety profile in combination studies, or limited adoption after prior therapy would reduce peak-sales potential.
How does WELIREG compare with other targeted oncology drugs?
WELIREG has a stronger mechanism-based differentiation than many late-line RCC therapies, but its eligible population is narrower under the current label.
| Measure |
WELIREG |
Established RCC targeted drugs |
| Mechanism |
HIF-2α inhibition |
VEGF, mTOR, or immune pathway inhibition |
| Administration |
Oral tablet |
Mostly oral, with some intravenous regimens |
| Initial disease focus |
VHL and previously treated advanced RCC |
Broad RCC populations |
| Regulatory exclusivity |
Orphan plus indication-specific protections |
Varies by product |
| Safety concern |
Anemia and hypoxia |
Hypertension, hand-foot syndrome, diarrhea, immune toxicity, or other class effects |
| Generic risk |
Later than near-term competitors if core patents hold |
Varies by product and patent estate |
| Differentiation |
First-in-class HIF-2α mechanism |
More established treatment history |
WELIREG’s first-in-class position supports pricing and physician interest, while its late-line RCC label limits immediate patient volume. The commercial outcome depends on whether Merck can convert mechanistic differentiation into earlier-line treatment use.
What generic launch scenarios exist for WELIREG?
Three scenarios are most relevant.
Scenario 1: Patent-protected launch delay
Merck maintains core patent protection through the mid-2030s, and generic entry occurs only after patent expiry or a court decision. This scenario supports continued premium pricing and gives Merck time to expand the franchise.
Scenario 2: Paragraph IV settlement
A generic company challenges the patents, and Merck settles by granting an agreed future entry date. The settlement may include a licensed generic, supply arrangement, or limited launch rights. This scenario creates a defined erosion date but may preserve several years of branded revenue.
Scenario 3: Early court victory for a generic
A generic applicant prevails on invalidity or non-infringement. Entry could then occur before the nominal patent expiration date, producing rapid price erosion. Oncology products can experience substantial volume migration after multiple generics enter, although branded prescribing may persist in VHL disease.
How broad is WELIREG’s geographic coverage?
Merck markets belzutifan internationally, but approval timing, reimbursement, and patent terms vary by jurisdiction. Key markets include the United States, European markets, Japan, and other countries with advanced oncology infrastructure.
Geographic commercial performance depends on:
- National reimbursement decisions.
- Recognition of VHL as an eligible indication.
- Local patent and supplementary protection certificate rights.
- Health-technology assessment conclusions.
- Availability of competing RCC therapies.
- Diagnostic identification of VHL patients.
The United States remains the most important market because of its earlier regulatory approval, higher oncology drug pricing, and stronger uptake in both VHL and advanced RCC.
What manufacturing and intellectual-property barriers affect WELIREG?
Belzutifan is a chemically synthesized small molecule, so manufacturing barriers are lower than for biologics. Generic manufacturers will not face cell-line development, biosimilar comparability, or complex biologic process controls.
The more relevant barriers are:
- Reproducing the active pharmaceutical ingredient at commercial scale.
- Meeting tablet dissolution and stability specifications.
- Demonstrating bioequivalence.
- Avoiding protected solid forms or manufacturing processes.
- Obtaining sufficient oncology manufacturing capacity.
- Resolving Orange Book certifications.
Because WELIREG is an oral tablet, the product is more vulnerable to standard generic substitution than injectable biologics. Patent claims, rather than manufacturing complexity, are likely to determine the length of effective exclusivity.
Key Takeaways
- WELIREG is Merck’s belzutifan, the first approved HIF-2α inhibitor.
- The 2023 advanced RCC approval transformed WELIREG from an orphan oncology product into a broader commercial asset.
- Revenue rose from approximately $240 million in 2022 to roughly $700 million in 2024.
- VHL provides a durable specialty market, while advanced RCC provides the main growth opportunity.
- Core belzutifan patent protection is generally expected to extend into the 2034-2036 period, with possible later secondary patents.
- VHL orphan exclusivity is expected to run through August 2028.
- WELIREG is a small molecule and will face ANDA-based generic competition rather than biosimilar competition.
- The principal commercial threats are RCC treatment sequencing, anemia and hypoxia, competing targeted therapies, and future HIF-2α products.
- Peak sales could reach the low-single-digit billions if Merck expands WELIREG into earlier-line or combination RCC treatment.
- The most important legal variables are Orange Book listings, Paragraph IV challenges, patent settlements, and the enforceability of compound and formulation claims.
FAQs
Is WELIREG a biologic or a small-molecule drug?
WELIREG is a small-molecule oral drug. Generic manufacturers would use the ANDA pathway rather than the biosimilar pathway.
Does WELIREG have orphan-drug exclusivity?
Yes. WELIREG received orphan-drug protection for its VHL-related indications. The seven-year exclusivity period is expected to run through August 2028, subject to the statutory scope of the orphan designation.
What is the main indication driving WELIREG sales?
Previously treated advanced renal cell carcinoma is the main large-market growth driver. VHL disease supports a smaller but strategically important specialty market.
Can a generic company launch WELIREG before 2034?
Potentially, but only through a successful patent challenge, a settlement-authorized entry, or another legally permitted route. Patent expiration alone does not determine the first possible generic launch date.
What is the principal safety limitation of belzutifan?
Anemia is the principal labeled safety concern, and hypoxia is also clinically important. Hemoglobin and oxygenation monitoring can affect treatment continuity and prescribing decisions.
References
- U.S. Food and Drug Administration. (2021). FDA approves belzutifan for von Hippel-Lindau disease.
- U.S. Food and Drug Administration. (2023). FDA approves belzutifan for advanced renal cell carcinoma.
- U.S. Food and Drug Administration. (2024). Welireg (belzutifan) prescribing information. Merck Sharp & Dohme LLC.
- Merck & Co., Inc. (2025). 2024 annual report.
- Merck & Co., Inc. (2019). Merck to acquire Peloton Therapeutics, including late-stage HIF-2α inhibitor program.
- U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.